- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06723210
Parkinson and the Males Body Composition (PD&MBC)
Parkinson´s Disease: Correlation Analysis Between the Cardinal Motor Symptoms of the Illness and the Male Patients´ Body Composition
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Oviedo, Spain, 33007
- University of Oviedo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
(I) Males with diagnosis of idiopathic PD and rated 1-3 on the Hoehn and Yahr Scale.
(II) No type of dementia as assessed by the mini-mental state examination. (III) Between 50 and 69 years old (a specific range of ages of the illness´s onset).
(IV) Between one and five years diagnosed with the illness. (V) Able to stand for two min without assistance. (VI) Able to walk teen m without assistance.
Exclusion Criteria:
(I) Do not meet the eligibility criteria. (II) Suffer a neurological disease other than Parkinson´s disease.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Patients
The patients were assigned to the same group because the study´s design only demands to create one group of patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The body composition variables or the bioelectrical impedance variables
Time Frame: From February 2025 to February 2025
|
weight (kg), fat-free mass in absolute terms (FFMa) (kg), fat-free mass in relative terms (FFMr) (normalized per kg of body mass -kg/kg of body weight-), fat-free mass of the right arm (FFMRA) (kg), fat-free mass of the left arm (FFMLA) (kfg), difference between the FFMRA and the FFMLA (%), fat-free mass of the right leg (FFMRL) (kg), fat-free of the mass left leg (FFMLL) (kg), difference between the FFMRL and the FFMLL (%), body fat mass (BFM) (kg), skeletal muscle mass (SMM) (kg), body mass index (BMI) (kg/m2), percentage body fat (PBF) (%), total body water in absolute terms (TBWa) (L), total body water in relative terms (TBWr) (normalized per kg of body mass -kg/kg of body weight-), total water of the right arm (TWRA) (L), total water of the left arm (TWLA) (L), difference between the TWRA and the TWLA (%), total water of the right leg (TWRL) (L), total water of the left leg (TWLL) (L), difference between the TWRL and the TWLL (%), intracellular water (ICW) (L), extracellular
|
From February 2025 to February 2025
|
|
The Movement Disorder Society-Unified Parkinson´s Disease Rating Scale (MDS-UPDRS))
Time Frame: From February 2025 to February 2025
|
MDS-UPDRS: Spanish validated version of the MDS-UPDRS.
The possible score ranges from 0 to 72 points whereby 0 points represent a healthy status and the more points, the worse health status.
|
From February 2025 to February 2025
|
|
The Ten-Meter Walk Test
Time Frame: From February 2025 to February 2025
|
The Ten-Meter Walk Test: performance measure used to assess walking speed in meters per second over a short distance (10 meters).
|
From February 2025 to February 2025
|
|
Step length
Time Frame: From February 2025 to February 2025
|
The step length of the patients will be determined using kinematic gait analysis during the TMWT, utilizing the OptoGait system (Microgait, Optogait, v.1.12.21,
Italy).
The step length of the patients will be determined in cm.
This system consists of transmitter and receiver bars equipped with optical sensors operating at a frequency of 1000 Hz, which will be positioned along the ten-meter walking corridor, from meter two to meter seven.
|
From February 2025 to February 2025
|
|
: Spanish validated version of the Disability of the Arm, Shoulder and Hand (DASH)
Time Frame: From February 2025 to February 2025
|
DASH: Spanish validated version of the Disability of the Arm, Shoulder and Hand.
The possible score ranges from 0 (which means no disability) to 100 (which means most severe disability).
Higher scores indicate a greater level of disability and severity, whereas, lower scores indicate a lower level of disability.
|
From February 2025 to February 2025
|
|
The Timed up and Go Test (TUG)
Time Frame: From February 2025 to February 2025
|
TUG: The TUG measures of functional mobility that was initially developed to identify mobility and balance impairments.
Participants takes to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while turning 180 degrees, as fast as they can (the time of the test is determined in sec).
|
From February 2025 to February 2025
|
|
Handgrip Strength of both hands.
Time Frame: From February 2025 to February 2025
|
Handgrip Strength of both hands: manual dynamometer measured in kilograms.
|
From February 2025 to February 2025
|
|
Static posturography
Time Frame: From February 2025 to February 2025
|
Static posturography, assessed by measurement of the center of pressure (CoP).
These CoP parameters; Length, in mm, Area in mm2 and Speed, Xspeed and Yspeed in m/s will be combined to report the patient´s static posturography.
|
From February 2025 to February 2025
|
|
The nine holes peg test (9-HPT)
Time Frame: From February 2025 to February 2025
|
The nine holes peg test (9-HPT) is a brief, standardized, quantitative test of upper extremity function.
Both the dominant and non-dominant hands are tested twice.
The patient is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes.
On a start command when a stopwatch is started, the patient picks up the nine pegs one at a time as quickly as possible, puts them in the nine holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into the shallow container.
The total time to complete the task is recorded in minutes.
Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand.
The score for the 9-HPT is an average of the four trials.
The two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged.
|
From February 2025 to February 2025
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ETICA-ULE-081-2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurodegenerative Disease
-
University of PennsylvaniaAvid RadiopharmaceuticalsRecruiting
-
ACADIA Pharmaceuticals Inc.CompletedNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseUnited States, Russian Federation, Serbia, Poland, Georgia, Czechia, Bulgaria, Colombia, Mexico, Romania, South Africa, Ukraine
-
Tianjin Medical UniversityTianjin Medical University General HospitalRecruitingTauopathies | Neurodegenerative Disease | Alzheimer s DiseaseChina
-
ACADIA Pharmaceuticals Inc.CompletedNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseSerbia, United States, Poland, Georgia, Russian Federation, Bulgaria, Colombia, Czechia, Mexico, Romania, South Africa, Ukraine
-
University of Illinois at Urbana-ChampaignRecruitingAdults | Mindfulness | EEG | Neurodegenerative DiseaseUnited States
-
National Institute of Neurological Disorders and...Completed
-
Cionic, Inc.Enrolling by invitationUpper Motor Neuron DiseaseUnited States
-
Xuanwu Hospital, BeijingCompletedNeuro-Degenerative Disease
-
University Health Network, TorontoRecruiting
-
Chinese University of Hong KongEnrolling by invitationNeuro-Degenerative DiseaseHong Kong